MedTrace Logo

Choline Dose Ranging in Postmenopausal Women

NCT06924541 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2026-05-04

No results posted yet for this study

Summary

This study will use a randomized placebo-controlled trial to examine smaller doses of choline and whether a signal in the brain is detectable using fMRI. This study will examine if an even smaller doses of choline can show these similar brain activation and connectivity patterns to the 1650 mg dose. This will be a dose ranging study of 550 mg and 1100 mg oral choline compared to placebo.

Conditions

Interventions

DIETARY_SUPPLEMENT

Choline

Each subject gets one of two oral choline doses or placebo on each of three study days, 550 mg, 1100 mg, and placebo

DIETARY_SUPPLEMENT

Placebo

Each subject gets one of two oral choline doses or placebo on each of three study days, 550 mg, 1100 mg, and placebo

Sponsors & Collaborators

  • Julie Dumas

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
50 Years
Max Age
65 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-09-01
Primary Completion
2025-12-01
Completion
2026-03-01

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06924541 on ClinicalTrials.gov